Digene/Cytyc Product Supplier Snatched Up By Cooper Unit In $12 Mil. Deal
This article was originally published in The Gray Sheet
Executive Summary
Cooper Surgical's purchase of Digene supplier Medscand Medical poises Cooper to benefit from the HPV test manufacturer's pursuit of a primary screening indication for the Hybrid Capture 2 (HC2).
You may also be interested in...
NCI HPV Trial Data Re-Evaluated By Digene To Support PMA Supplement
Digene will reanalyze clinical data and specimens from a 23,702-patient trial in Portland, Oregon, prior to seeking a primary screening indication for its HybridCapture 2 HPV test. The Gaithersburg, Maryland firm expects to file a PMA supplement by year-end.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.